Published in Nature on August 13, 2014
Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol (2014) 1.48
Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med (2015) 1.30
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature (2016) 1.20
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog (2015) 1.11
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med (2016) 1.03
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol (2015) 0.98
Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun (2016) 0.95
Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol (2015) 0.91
Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. J Virol (2015) 0.88
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog (2016) 0.88
Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. Curr Opin HIV AIDS (2015) 0.87
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest (2016) 0.85
Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. PLoS Pathog (2015) 0.85
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev (2015) 0.84
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J Immunol (2015) 0.84
CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol (2014) 0.84
Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS (2015) 0.83
Animal models in HIV-1 protection and therapy. Curr Opin HIV AIDS (2015) 0.83
Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr Opin HIV AIDS (2015) 0.82
The role of Fc receptors in HIV prevention and therapy. Immunol Rev (2015) 0.81
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs (2015) 0.81
TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol Rev (2015) 0.81
Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. AIDS (2016) 0.80
HIV antibodies for treatment of HIV infection. Immunol Rev (2017) 0.80
Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol (2016) 0.80
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev (2016) 0.80
Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. AIDS (2016) 0.80
Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. J Virol (2016) 0.80
Targeting FcRn for the modulation of antibody dynamics. Mol Immunol (2015) 0.80
Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev (2017) 0.80
Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. Mucosal Immunol (2016) 0.78
Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev (2017) 0.77
Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. MAbs (2016) 0.77
Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. Oncotarget (2016) 0.77
Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. MAbs (2015) 0.77
Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. AIDS (2017) 0.76
Antibodies for prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS (2015) 0.76
HIV: Potency needs constancy. Nature (2014) 0.76
Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization. Front Microbiol (2016) 0.76
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr Opin HIV AIDS (2017) 0.75
Naturally Occurring Fc-Dependent Antibody From HIV-Seronegative Individuals Promotes HIV-Induced IFN-α Production. Sci Rep (2016) 0.75
Enhancement of antibody functions through Fc multiplications. MAbs (2017) 0.75
Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. Front Immunol (2017) 0.75
Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti Infect Ther (2015) 0.75
Eliminating antibody polyreactivity through addition of N-linked glycosylation. Protein Sci (2015) 0.75
Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Curr HIV/AIDS Rep (2017) 0.75
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr Opin HIV AIDS (2017) 0.75
Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. Int J Mol Sci (2016) 0.75
Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. PLoS Pathog (2017) 0.75
Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers. Pharm Res (2017) 0.75
Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys. Mol Ther (2017) 0.75
Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys. Gene Ther (2017) 0.75
Virological control by the CD4-binding site antibody N6 in SHIV-infected rhesus monkeys. J Virol (2017) 0.75
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci U S A (1969) 5.90
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol (2003) 3.09
Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity (2004) 2.79
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest (2011) 2.55
Enhanced antibody half-life improves in vivo activity. Nat Biotechnol (2010) 2.33
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol (2006) 2.32
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol (2013) 2.22
Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A (2011) 2.14
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods (2005) 2.03
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine (2006) 1.99
An engineered human IgG1 antibody with longer serum half-life. J Immunol (2006) 1.88
Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A (2004) 1.69
Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis (1991) 1.66
Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin. J Biol Chem (2002) 1.58
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med (2014) 1.49
Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules. Proc Natl Acad Sci U S A (1992) 1.44
Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol (2009) 1.42
Poliovirus type 1 enters the human host through intestinal M cells. Gastroenterology (1990) 1.31
Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol (2012) 1.27
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother (2013) 1.24
Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity (2013) 1.07
Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J Virol (2013) 1.01